Studying Genetic Changes in Fat Tissue Near Retroperitoneal Liposarcoma
Collects fat samples during surgery to study genetic changes linked to liposarcoma recurrence in adults.
Key facts
- Who runs it
- Fox Chase Cancer Center
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Genomic Risk in Retroperitoneal Sarcoma
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 7 Mar 2022
- Expected to end
- 1 Aug 2027
- Type of study
- Observational
- Treatments tested
- Biospecimen sample collection during standard-of-care surgery
- Record updated
- 31 May 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with retroperitoneal liposarcoma who will have surgery to remove the tumor. Small samples of retroperitoneal fat are taken during the operation and tested for gene changes.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Retroperitoneal liposarcoma confirmed by a biopsy before surgery, or scans that look like liposarcoma with surgery planned. It can be a first tumor or one that came back.
- Earlier treatment
- Surgery to remove the tumor must be planned.
Main reasons for not taking part
- Earlier surgery that makes sampling of distant areas of the retroperitoneum impossible or unsafe
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adult patients (age ≥18 years)
- Histologically confirmed retroperitoneal liposarcoma via preoperative biopsy, or cross-sectional imaging suspicious for liposarcoma with planned surgical resection
- Will be undergoing surgical resection for treatment of primary or recurrent disease
- Have provided informed consent to participate in this study
Who cannot take part
- Prior surgical anatomy which makes sampling of remote areas of the retroperitoneum technically impossible or clinically undesirable for safety reasons
Where in United States
- Fox Chase Cancer CenterPhiladelphia, United StatesContact: Anthony Villano, MDTaking people
About the trial
What the trial wants to find out
The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.
The group in the trial
- Cohort 1
The entire study is a singular cohort of patients with retroperitoneal liposarcoma (index or recurrent) who undergo surgical resection of their tumor.
Treatment: Biospecimen sample collection during standard-of-care surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Characterization of the Genomic Risk Underlying Retroperitoneal Liposarcoma
- Plain-language title
- Studying Genetic Changes in Fat Tissue Near Retroperitoneal LiposarcomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 31 May 2024